---
title: "Xilio Therapeutics (XLO) news: going concern and offering"
url: "https://aibio.space/companies/xilio-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "XLO going concern, offering and Nasdaq notice news: Xilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price."
---

XLO Xilio Therapeutics, Inc. NASDAQ · United States

# Xilio Therapeutics (XLO) news XLO going concern, offering and Nasdaq notice news

Listings · 2025-10-03

## [Xilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price](https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-until-march-30/)

Xilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.

## Latest Xilio Therapeutics news

1. 2025-10-03 Listings [Xilio Therapeutics moves to Nasdaq Capital Market, gets 180 more days on $1.00 bid rule](https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-180-more-days-1-00/) Nasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.
2. 2025-08-28 Listings [Xilio Therapeutics gets Nasdaq notice over stockholders' equity below $10.0 million](https://aibio.space/news/xilio-therapeutics-gets-nasdaq-notice-stockholders-equity-below-10-0/) Nasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.
3. 2025-03-11 Financings [Xilio Therapeutics sets up $50,000,000 at-the-market stock program with Leerink](https://aibio.space/news/xilio-therapeutics-sets-up-50-000-000-market-stock-program-leerink/) Leerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.

## Xilio Therapeutics at a glance

- **Ticker**: XLO

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $136.0 million

### Related companies

- [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII
- [Pacira BioSciences](https://aibio.space/companies/pacira-biosciences/) NASDAQ: PCRX
- [Belite Bio](https://aibio.space/companies/belite-bio/) NASDAQ: BLTE
- [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH
- [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD
- [Bristol-Myers Squibb](https://aibio.space/companies/bristol-myers-squibb/) NYSE: BMY
- [HARD TO TREAT DISEASES INC](https://aibio.space/companies/hard-to-treat-diseases/) OTC: HTDS
- [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) NASDAQ: ALGS

### Also on NASDAQ

- [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) REGN
- [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) HURA
- [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) SKYE
- [BIOHARVEST SCIENCES INC.](https://aibio.space/companies/bioharvest-sciences/) BHST
- [HCW Biologics](https://aibio.space/companies/hcw-biologics/) HCWB
- [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) PRLD

## Xilio Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$43.8 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) |
| Research and development | [$56.0 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) | [$41.2 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) |
| Net income (loss) | [-$35.0 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) | [-$58.2 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) |
| Cash from operations | [-$5.0 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) | [-$18.4 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) |
| Cash and equivalents | [$137.5 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526345759/) | [$55.3 million](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $136.0 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Xilio Therapeutics

Has Xilio Therapeutics issued a going-concern warning?

Our latest story on this, dated Oct 3, 2025: "Xilio Therapeutics moves to Nasdaq Capital Market, gets until March 30, 2026 on bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-until-march-30/).

Has Xilio Therapeutics raised money recently?

Our latest story on this, dated Mar 11, 2025: "Xilio Therapeutics sets up $50,000,000 at-the-market stock program with Leerink". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xilio-therapeutics-sets-up-50-000-000-market-stock-program-leerink/).

Has Xilio Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 28, 2025: "Xilio Therapeutics gets Nasdaq notice over stockholders' equity below $10.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xilio-therapeutics-gets-nasdaq-notice-stockholders-equity-below-10-0/).

What is the ticker symbol of Xilio Therapeutics?

Xilio Therapeutics, Inc. trades under the ticker XLO on NASDAQ.

Where is Xilio Therapeutics listed?

Xilio Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Xilio Therapeutics?

The SEC Central Index Key (CIK) for Xilio Therapeutics, Inc. is 1840233. Its filings are on SEC EDGAR.

How many shares does Xilio Therapeutics have outstanding?

5,782,511 shares as of 2026-03-18, per the cover page of its 10-K filed 2026-03-23.

Which country or territory is Xilio Therapeutics listed under?

Our directory records Xilio Therapeutics, Inc. under United States.

What does Xilio Therapeutics do?

Our directory classifies Xilio Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Xilio Therapeutics?

The ISIN recorded for Xilio Therapeutics, Inc. is US98422T2096.

Does aibio.space cover Xilio Therapeutics?

aibio.space lists Xilio Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Xilio Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What was Xilio Therapeutics's revenue last year?

$43.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Xilio Therapeutics profitable?

Xilio Therapeutics, Inc. reported a net loss of $35.0 million for the fiscal year ended Dec 31, 2025, and used $5.0 million of cash in operations, per its annual report to the SEC.

How much does Xilio Therapeutics spend on research and development?

$56.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: Xilio Therapeutics

Members talk about Xilio Therapeutics (XLO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Xilio Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-03-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/xlo-ex99_1.htm)
2. 2026-02-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/xlo-20260223.htm)
3. 2026-02-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526046842/d107955d424b5.htm)
4. 2026-01-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526021691/xlo-20260122.htm)
5. 2026-01-16 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526015343/xlo-20260116.htm)
6. 2026-01-05 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/xlo-20260102.htm)
7. 2025-10-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/d74952d8k.htm)
8. 2025-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/xlo-20250822x8k.htm)
9. 2025-04-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000155837025004599/xlo-20250404x8k.htm)
10. 2025-03-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1840233/000119312525051529/d896243d424b5.htm)
11. 2025-02-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000155837025000823/xlo-20250210xex99d1.htm)
12. 2024-12-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/xlo-20241218xex99d1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:XLO on TradingView](https://www.tradingview.com/symbols/NASDAQ-XLO/).

## SEC filings and registration

- **SEC name**: Xilio Therapeutics, Inc.

- **CIK**: 1840233

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: XLO (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 828 WINTER STREET, WALTHAM, MA, 02451

- **Phone**: 617-833-1027

- **Shares outstanding**: 5,782,511 as of 2026-03-18 (10-K filed 2026-03-23)

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1840233/000119312526345759/xlo-20260630.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-20260812.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/xlo-20260610.htm) filed 2026-06-12
- [S-3](https://www.sec.gov/Archives/edgar/data/1840233/000119312526218212/xlo-20260512.htm) filed 2026-05-12
- [10-Q](https://www.sec.gov/Archives/edgar/data/1840233/000119312526218200/xlo-20260331.htm) filed 2026-05-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-20260512.htm) filed 2026-05-12
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1840233/000119312526187642/xlo-20260428.htm) filed 2026-04-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1840233/000119312526157940/xlo-20260416.htm) filed 2026-04-16

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001840233), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Xilio Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XLO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Xilio Therapeutics, Inc.

- **Ticker**: XLO

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US98422T2096

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-XLO/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/xilio-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Xilio Therapeutics (XLO) news: going concern and offering", 2026-10-31, https://aibio.space/companies/xilio-therapeutics/